KDNY News and Press, Chinook Therapeutics Inc Com From 05/24/22

Biopharmaceutical company Chinook Therapeutics (NASDAQ:KDNY) commenced an underwritten public offering of its common stock. In lieu of common stock, the company will also offer and sell to certain investors pre-funded warrants to purchase shares. KDNY intends to grant the underwriters a 30-da...

SEATTLE, May 24, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that it has commenced an underwritten public offering of i...

The AFFINITY IgAN cohort of 20 patients is fully enrolled, with 70% of patients in the study having baseline proteinuria over one gram per day despite maximal RAS inhibitor treatment, representing an IgAN patient population at high risk for progression Atrasentan was w...

All patients with IgAN in Cohort 1 have transitioned to subcutaneous (SC) dosing, and BION-1301 remains well-tolerated, with no serious adverse events (SAEs) and no treatment discontinuations due to adverse events (AEs) BION-1301 continues to demonstrate rapid and sust...

Chinook Therapeutics press release (NASDAQ:KDNY): Q1 GAAP EPS of -$0.54 beats by $0.11. Revenue of $2.7M (+671.4% Y/Y). For further details see: Chinook Therapeutics GAAP EPS of -$0.54 beats by $0.11, revenue of $2.7M

SEATTLE, May 12, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the fi...

Data on atrasentan to be presented in an oral presentation from the IgA nephropathy (IgAN) patient cohort of the phase 2 AFFINITY basket trial Updated data to be presented from Cohort 1 of Part 3 of the ongoing phase 1/2 study of BION-1301 in patients with IgAN Addit...

SEATTLE, April 25, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to present and part...

Chinook Therapeutics (NASDAQ:KDNY) began dosing in a phase 1 trial of CHK-336 in adult healthy volunteers. The company is developing CHK-336 for treating patients with primary hyperoxaluria (PH) and secondary hyperoxaluria due to increased endogenous oxalate production. Hyperoxalurias occurs ...

SEATTLE, April 12, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that dosing has been initiated in a phase 1 clinical tri...